Ayurvedic Rasayana therapies

Not yet recruiting

Conditions: Coronavirus as the cause of diseases classified elsewhere,

Registration Number: CTRI/2020/07/026700

Lead Sponsor: Ayurved Rasayani

Brief Summary: Hypothesis: SARS-CoV-2 is a rapidly spreading viral infection causing coronavirus disease. The current strategy for dealing with this pandemic is to identify infected cases and their contacts, screening, isolation, and quarantine to stop spread of the disease. Post exposure to COVID -19 the standard of care is observation of the individual under quarantined condition. Therapy is generally not given to persons who are not hospitalized. Ayurveda medicines have a long-term history of use in clinics for overall immunity building. This has created evidence for its efficacy in various respiratory disorders and also safety is demonstrated. Administration of oral Ayurveda Rasayana formulations will help reduce the risk of development of symptomatic corona virus disease or can prevent disease progression, thereby decreasing hospitalizations and symptoms severity.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 200

Inclusion Criteria

1 18 years or older 2 If an individual has come in close contact with someone who has been diagnosed with COVID 19 with last exposure within the last 4 days and do not have any symptoms or 3 A healthcare worker involved in care of patients with Coronavirus disease.

Exclusion Criteria

1 Immunocompromised patients or patients receiving immuno-compromised medications 2 Patients with active malignancy or undergoing anticancer therapies 3 Pregnant women or women who are breastfeeding 4 Consideration by the investigator for any reason that the subject is an unsuitable 5 candidate to receive study treatment Patients not willing to participate in study.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate if Ayurveda Rasayana therapy can prevent symptomatic coronavirus disease or	Day 1 \| Day 30 and \| Day 60
severe corona virus disease after known exposure to the SARS-CoV-2 coronavirus	Day 1 \| Day 30 and \| Day 60

Secondary Outcome Measures

Name	Time	Method
Evaluation of Pro inflammatory cytokines.	Disease severity on an ordinal scale.

Trial Locations

Locations (2): Symbiosis Medical collage for woman
🇮🇳
Pune, MAHARASHTRA, India
Yashwantrao Chavan Memorial Hospital YCM Hospital Rd Sant Tukaram Nagar Pimpri Colony Pune
🇮🇳
Pune, MAHARASHTRA, India
Symbiosis Medical collage for woman
🇮🇳Pune, MAHARASHTRA, India
DrMeenakshi Bhakare
Principal investigator
9096555775
hod.respiratorymedicine@smcw.siu.edu.in